In an 80‑year‑old patient with chronic kidney disease stage 3b‑4 and a serum magnesium of 1.16 mmol/L (mild hypermagnesemia), is it safe to continue a 300 mg magnesium glycinate supplement?

Discontinue the magnesium glycinate supplement immediately

In an 80-year-old patient with CKD stage 3b-4 and serum magnesium of 1.16 mmol/L (2.82 mg/dL), you must stop the 300 mg magnesium glycinate supplement due to existing mild hypermagnesemia and high risk of progression to dangerous hypermagnesemia.

Why This Decision is Critical

Your patient already has mild hypermagnesemia (normal range: 1.7-2.4 mg/dL or 0.7-1.0 mmol/L). The serum magnesium of 1.16 mmol/L converts to approximately 2.82 mg/dL, which exceeds the normal upper limit. Continuing supplementation in advanced CKD creates substantial risk:

The Evidence Against Continuation

Hypermagnesemia predicts mortality in CKD patients. The most definitive study on this topic found that hypermagnesemia (defined as ≥3.0 mg/dL) was independently associated with increased all-cause mortality (HR=1.54, P=.049) and cardiovascular events (HR=1.34, P=.037) in CKD patients 1. Your patient is already approaching this dangerous threshold.

CKD stage 4 is the strongest risk factor for hypermagnesemia. In patients taking daily magnesium oxide, CKD grade 4 was significantly associated with both hypermagnesemia (p=0.014) and high serum magnesium concentration (p<0.001) 2. Your patient with CKD 3b-4 has severely impaired magnesium excretion capacity.

KDIGO Guidelines Support Discontinuation

The 2024 KDIGO guidelines explicitly state that you should "review and limit the use of over-the-counter medicines and dietary or herbal remedies that may be harmful for people with CKD" 3. The guidelines emphasize that "people with CKD may be more susceptible to the nephrotoxic effects of medications" and require careful consideration of "benefits versus potential harms" 3.

You must monitor electrolytes in CKD patients receiving supplements, particularly those with "narrow therapeutic windows" or "potential adverse effects" 3. Magnesium clearly falls into this category given the patient's existing hypermagnesemia.

The Nuanced Evidence on Magnesium in CKD

There is a paradox in the literature that requires careful interpretation:

• Low magnesium is harmful: Hypomagnesemia is associated with CKD progression, vascular calcification, and mortality 4, 5, 6
• High magnesium is also harmful: Hypermagnesemia predicts cardiovascular events and death 1

The key distinction: supplementation studies showing benefit were conducted in patients with normal or LOW baseline magnesium levels, not in patients who already have hypermagnesemia. One randomized trial showed magnesium oxide could slow coronary artery calcification in non-dialysis CKD patients 6, but this does not apply when magnesium is already elevated.

Clinical Algorithm for This Patient

1. Immediate action: Stop magnesium glycinate supplement
2. Recheck serum magnesium in 2-4 weeks to confirm downward trend
3. Review all medications for magnesium-containing compounds (antacids, laxatives, PPIs which paradoxically can affect magnesium) 3
4. Target serum magnesium: Aim for 2.0-2.5 mg/dL (0.82-1.02 mmol/L) - the "sweet spot" where mortality is lowest in CKD patients 1
5. If magnesium drops below 2.0 mg/dL: Consider reintroducing at lower dose (e.g., 100-150 mg elemental magnesium) with close monitoring

Critical Pitfalls to Avoid

Do not continue supplementation based on general population data. The 350 mg/day threshold identified in healthy adults aged 50+ 7 does not apply to advanced CKD where renal excretion is impaired.

Do not assume the supplement is safe because it's "natural." The FDA labeling warns to "not exceed recommended dose" and to "consult with your physician" 8. In CKD 3b-4, even recommended doses can accumulate dangerously.

Do not wait for symptoms. Hypermagnesemia can cause neuromuscular depression, cardiac conduction abnormalities, and hypotension before becoming clinically obvious. The patient's age (80 years) increases vulnerability to these effects.

The Bottom Line

While magnesium supplementation may benefit CKD patients with hypomagnesemia, your patient has the opposite problem. The combination of existing hypermagnesemia, advanced CKD (stage 3b-4), and continued supplementation creates unacceptable risk. The evidence clearly shows worse outcomes at magnesium levels your patient is approaching 1. Discontinuation is not just reasonable—it is medically necessary.